ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $85 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $12.8 million of additional shares of its common stock.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
